CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Sub-Licensee Partner Announces CRO for Phase 1 and Phase 2 Berubicin Trials in Poland
Poland trials will include the first ever Phase 1 trial for pediatric patients suffering from glioblastoma multiforme CNS Pharmaceuticals has…